FILSPARI (sparsentan)Prescribing Information Update
Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile
Sparsentan Has Direct Effects on the Glomerular Capillary Wall to Attentuate Increased Permeability After Exposure to Nephrotic Syndrome Plasma
American Nephrology Nurses Association (ANNA) Annual Symposium 2024
April 14 - 17, 2024
FL
American Society of Nephrology (ASN) Kidney Week 2024
October 23 - 27, 2024
CA
PROTECT and NefIgArd 2-Year Proteinuria and eGFR Outcomes in Adults with IgA Nephropathy: Matching-Adjusted Indirect Comparison (MAIC)
Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT study with UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd
Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety
European Renal Association (ERA) Congress 2024
May 23 - 26, 2024
Stockholm
FILSPARI (sparsentan): Impact on Male Fertility
FILSPARI (sparsentan): Use in Transplant Patients
FILSPARI (sparsentan): Use in Patients With Severely Decreased eGFR in IgA Nephropathy
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study